share_log

Shinva Medical Instrument Co., Ltd.'s (SHSE:600587) Stock Is Going Strong: Have Financials A Role To Play?

Shinva Medical Instrument Co., Ltd.'s (SHSE:600587) Stock Is Going Strong: Have Financials A Role To Play?

新華醫療器械股份有限公司 's(瑞士證券交易所:600587) 股票走強:有財務發揮作用?
Simply Wall St ·  2023/02/22 08:12

Shinva Medical Instrument's (SHSE:600587) stock is up by a considerable 13% over the past three months. We wonder if and what role the company's financials play in that price change as a company's long-term fundamentals usually dictate market outcomes. In this article, we decided to focus on Shinva Medical Instrument's ROE.

新華醫療器械(上海證券交易所代碼:600587)的股票在過去三個月裏大幅上漲了13%。我們想知道,由於一家公司的長期基本面通常決定着市場結果,該公司的財務狀況是否以及在價格變化中扮演了什麼角色。在本文中,我們決定將重點放在Shinva醫療器械的ROE上。

Return on equity or ROE is an important factor to be considered by a shareholder because it tells them how effectively their capital is being reinvested. Put another way, it reveals the company's success at turning shareholder investments into profits.

股本回報率或淨資產收益率是股東要考慮的一個重要因素,因為它告訴他們他們的資本再投資的效率。換句話説,它揭示了該公司成功地將股東投資轉化為利潤。

View our latest analysis for Shinva Medical Instrument

查看我們對Shinva醫療器械的最新分析

How To Calculate Return On Equity?

如何計算股本回報率?

ROE can be calculated by using the formula:

可使用以下公式計算淨資產收益率:

Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity

股本回報率=(持續經營的)淨利潤?股東權益

So, based on the above formula, the ROE for Shinva Medical Instrument is:

因此,根據上面的公式,Shinva醫療器械的淨資產收益率為:

9.8% = CN¥553m ÷ CN¥5.6b (Based on the trailing twelve months to September 2022).

9.8%=5.53億元×56億元(以截至2022年9月的12個月為基礎)。

The 'return' is the profit over the last twelve months. One way to conceptualize this is that for each CN¥1 of shareholders' capital it has, the company made CN¥0.10 in profit.

“收益”是過去12個月的利潤。一種概念化的方法是,公司每擁有1元人民幣的股東資本,就會獲得0.10元人民幣的利潤。

Why Is ROE Important For Earnings Growth?

為什麼淨資產收益率對收益增長很重要?

We have already established that ROE serves as an efficient profit-generating gauge for a company's future earnings. We now need to evaluate how much profit the company reinvests or "retains" for future growth which then gives us an idea about the growth potential of the company. Generally speaking, other things being equal, firms with a high return on equity and profit retention, have a higher growth rate than firms that don't share these attributes.

我們已經證實,淨資產收益率是一家公司未來收益的有效盈利指標。我們現在需要評估公司將多少利潤再投資或“保留”用於未來的增長,這就讓我們對公司的增長潛力有了一個瞭解。一般來説,在其他條件相同的情況下,股本回報率和利潤留存較高的公司比不具備這些特徵的公司有更高的增長率。

Shinva Medical Instrument's Earnings Growth And 9.8% ROE

申華醫療器械的盈利增長和9.8%的淨資產收益率

At first glance, Shinva Medical Instrument's ROE doesn't look very promising. However, given that the company's ROE is similar to the average industry ROE of 11%, we may spare it some thought. Looking at Shinva Medical Instrument's exceptional 26% five-year net income growth in particular, we are definitely impressed. Considering the moderately low ROE, it is quite possible that there might be some other aspects that are positively influencing the company's earnings growth. Such as - high earnings retention or an efficient management in place.

乍一看,信華醫療器械的淨資產收益率(ROE)看起來並不是很有希望。然而,鑑於該公司的淨資產收益率(ROE)接近11%的行業平均淨資產收益率,我們或許可以省去一些思考。尤其是Shinva醫療器械公司五年來26%的非凡淨收入增長,給我們留下了深刻的印象。考慮到較低的淨資產收益率,很有可能還有一些其他方面正在積極影響公司的收益增長。例如-高收益留存或有效的管理到位。

Next, on comparing Shinva Medical Instrument's net income growth with the industry, we found that the company's reported growth is similar to the industry average growth rate of 24% in the same period.

接下來,將申華醫療器械的淨收入增長與行業進行比較,我們發現,該公司的報告增長與同期24%的行業平均增長率相似。

past-earnings-growth
SHSE:600587 Past Earnings Growth February 22nd 2023
上證所:過去600587的收益增長2023年2月22日

Earnings growth is an important metric to consider when valuing a stock. The investor should try to establish if the expected growth or decline in earnings, whichever the case may be, is priced in. By doing so, they will have an idea if the stock is headed into clear blue waters or if swampy waters await. One good indicator of expected earnings growth is the P/E ratio which determines the price the market is willing to pay for a stock based on its earnings prospects. So, you may want to check if Shinva Medical Instrument is trading on a high P/E or a low P/E, relative to its industry.

盈利增長是評估一隻股票時需要考慮的一個重要指標。投資者應該嘗試確定預期的收益增長或下降是否已計入價格,無論是哪種情況。通過這樣做,他們將知道股票是將進入清澈的藍色水域,還是等待沼澤水域。衡量預期收益增長的一個很好的指標是市盈率,它根據一隻股票的盈利前景決定市場願意為其支付的價格。因此,你可能想要檢查Shinva醫療器械相對於其行業是高市盈率還是低市盈率。

Is Shinva Medical Instrument Making Efficient Use Of Its Profits?

Shinva醫療器械是否有效利用了其利潤?

Shinva Medical Instrument has a really low three-year median payout ratio of 11%, meaning that it has the remaining 89% left over to reinvest into its business. This suggests that the management is reinvesting most of the profits to grow the business as evidenced by the growth seen by the company.

信華醫療器械的三年中值派息率非常低,只有11%,這意味着它還有剩餘的89%用於再投資於業務。這表明管理層正在將大部分利潤進行再投資,以實現業務增長,公司的增長就是明證。

Additionally, Shinva Medical Instrument has paid dividends over a period of at least ten years which means that the company is pretty serious about sharing its profits with shareholders.

此外,Shinva醫療器械在至少十年的時間裏支付了股息,這意味着該公司非常認真地與股東分享利潤。

Conclusion

結論

Overall, we feel that Shinva Medical Instrument certainly does have some positive factors to consider. Despite its low rate of return, the fact that the company reinvests a very high portion of its profits into its business, no doubt contributed to its high earnings growth. While we won't completely dismiss the company, what we would do, is try to ascertain how risky the business is to make a more informed decision around the company. Our risks dashboard will have the 1 risk we have identified for Shinva Medical Instrument.

總體而言,我們認為Shinva醫療器械確實有一些積極的因素需要考慮。儘管回報率很低,但該公司將很高比例的利潤再投資於業務,無疑是其高收益增長的原因。雖然我們不會完全解僱這家公司,但我們要做的是努力確定這項業務在公司周圍做出更明智的決定的風險有多大。我們的風險控制面板將包含我們為Shinva醫療器械確定的1個風險。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有什麼反饋嗎?擔心內容嗎? 保持聯繫直接與我們聯繫。或者,也可以給編輯組發電子郵件,地址是implywallst.com。
本文由Simply Wall St.撰寫,具有概括性。我們僅使用不偏不倚的方法提供基於歷史數據和分析師預測的評論,我們的文章並不打算作為財務建議。它不構成買賣任何股票的建議,也沒有考慮你的目標或你的財務狀況。我們的目標是為您帶來由基本面數據驅動的長期重點分析。請注意,我們的分析可能不會將最新的對價格敏感的公司公告或定性材料考慮在內。Simply Wall St.對上述任何一隻股票都沒有持倉。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論